VEGFA and wet macular degeneration: Although treatments such as anti-vascular endothelial growth factor (VEGF) agents for wet AMD and emerging complement inhibitors for dry AMD have advanced care, limitations persist, including inconsistent treatment responses and the absence of effective early-stage interventions.